Valuation
- Market cap
- 302,453,000
- Revenue TTM
- $12,140,000
- Net income TTM
- $-99,500,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -819.60%
- Debt to equity
- 0.00
Trading
- Volume
- 742,000
- Avg volume
- 525,508
- Day's range
- $3.63 – $3.82
- Shares out
- 79,803,000
- Stochastic %K
- 6%
- Beta
- 0.97
- Analysts
- Strong Sell
- Price target
- $9.00
Company profile
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and othe...
Show more
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 302 467 1280
- Website
- https://preludetx.com
- Address
- 175 Innovation Boulevard, Wilmington, United States
Latest news
No headlines yet.
